Fungal‑derived compounds and mycogenic nanoparticles with antimycobacterial activity: a review
Loading...
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Tuberculosis (TB) is a persistent lung infection caused by Mycobacterium tuberculosis. The disease is characterized by high
mortality rates of over 1 million per year. Unfortunately, the potency and efectiveness of currently used anti-TB drugs
is gradually decreasing due to the constant development of persistence and resistance by M. tuberculosis. The adverse
side efects associated with current anti-TB drugs, along with anti-TB drug resistance, present an opportunity to bioprospect novel potent anti-TB drugs from unique sources. Fundamentally, fungi are a rich source of bioactive secondary
metabolites with valuable therapeutic potential. Enhancing the potency and efectiveness of fungal-based anti-TB drug
leads by chemical synthesis and/or modifcation with nanomaterials, may result in the discovery of novel anti-TB drugs. In
this review, the antimycobacterial activity of fungal-derived compounds and mycogenic nanoparticles are summarized.
Numerous fungal-derived compounds as well as some mycogenic nanoparticles that exhibit strong antimycobacterial
activity that is comparable to that of approved drugs, were found. If fully explored, fungi holds the promise to become
key drivers in the generation of lead compounds in TB-drug discovery initiatives.
Description
Keywords
Mycobacterium tuberculosis, Fungi, Secondary metabolites, Bioprospecting, Drug discovery, Mycogenic nanoparticles
Citation
Tapfuma, K. I., Nyambo, K., Baatjies, L., Keyster, M., Mekuto, L., Smith, L., Allie, N., Loxton, A. G., Malgas-Enus, R., & Mavumengwana, V. (2022). Fungal-derived compounds and mycogenic nanoparticles with antimycobacterial activity: a review. SN Applied Sciences, 4(5). https://doi.org/10.1007/s42452-022-05010-2